Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UCB S.A.
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.
- Research, Analytical Equipment & Supplies
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Celltech Pharmaceuticals, Inc.
- Element Genomics
- Engage Therapeutics, Inc., Ra Pharmaceuticals, Inc.
- Schwarz Pharma
- Upstate Pharma, LLC